美施康定联合吲哚美辛栓治疗晚期癌痛患者疗效评估

目的评估美施康定联合吲哚美辛栓与单一大剂量应用美施康定临床的疗效。方法晚期癌痛患者140例随机分为2组:对照组75例和观察组65例。观察组给予小剂量美施康定口服及吲哚美辛栓纳肛,对照组仅给予美施康定口服。观察2组的有效率及不良反应发生率。结果对照组有效66例,观察组有效58例,差异无统计学意义(P>0.05)。2组不良反应发生率:头晕、恶心呕吐、便秘,差异均有统计学意义(P<0.05)。结论小剂量美施康定联合吲哚美辛栓治疗晚期癌痛患者疗效与单一大剂量应用美施康定相比副反应更小,且更经济,且止痛效果无明显差别。

MS contin combined with indometacin enteric in treatment of patients suffering from advanced cancer pain: An evaluation of therapeutic effect

Objective To evaluate the curative effect of MS contin combined with indometacin enteric in treatment of pa- tients suffering from advanced cancer pain. Methods 140 patients suffering from advanced cancer pain were randomly divided into 2 groups ： a control group （75 cases） and an observation group （65 cases）. The clinical data of the two groups showed no difference of significance （ P 〉 0.05 ）. The observation group was given a small dosage of MS contin and indometacin enteric. The two groups were observed in terms of effective rate and incidence rate of adverse reactions. Results （ Effectiveness ： 66 cases were effective in the control group in contrast with 58 cases in the observation group. There was no statistical difference between the two groups （P 〉 0.05 ）②Adverse reactions： dizziness, nausea and vomitting, and constipation occurred. The difference had statistical significance （ P 〈 0.05 ）. Conclusion There is no obvious difference between small dosage of MS contin combined with indometacin enteric and a single large dosage of MS contin in the treatment of advanced cancer pain. But the former has the advantage of being less adverse in reaction and more economical.